Ralyl is specific for liver progenitor cells and regulates hepatocellular carcinoma stem cells by upregulating the stability of TGF-β2 mRNA through the reduced N6-methyladenosine modification (Wang et al., 2021). Here, RALYL is linked to hepatocellular carcinoma.